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1. INTRODUCTION {#brb31704-sec-0005}
===============

Neurodegenerative Huntington\'s disease (HD) is caused by CAG trinucleotide expansion in the huntingtin gene (HTT; Walker, [2007](#brb31704-bib-0021){ref-type="ref"}). Symptomatic manifestation accompanies with heterogeneous motoric, cognitive, and psychiatric symptoms. Although dominant motor symptoms are hyperkinetic, they can vary manifold with bradykinesia, dystonia, myoclonus, or as hypokinetic‐rigid (Roos, [2010](#brb31704-bib-0013){ref-type="ref"}; Saft, Lauter, Kraus, Przuntek, & Andrich, [2006](#brb31704-bib-0014){ref-type="ref"}).

Several studies investigated different aspects of bradykinesia, respectively, hypokinetic‐rigidity or chorea in HD (Girotti, Marano, Soliveri, Geminiani, & Scigliano, [1988](#brb31704-bib-0003){ref-type="ref"}; Mahant, McCusker, Byth, & Graham, [2003](#brb31704-bib-0010){ref-type="ref"}; Reedeker, Van Der Mast, Giltay, Van Duijn, & Roos, [2010](#brb31704-bib-0012){ref-type="ref"}; Sanchez‐Pernaute et al., [2000](#brb31704-bib-0016){ref-type="ref"}; Thompson et al., [1988](#brb31704-bib-0018){ref-type="ref"}; Young et al., [1986](#brb31704-bib-0023){ref-type="ref"}). More recently, Hart et al. ([2013](#brb31704-bib-0004){ref-type="ref"}) focused on aspects of predominant choreatic versus hypokinetic‐rigid motor phenotypes and described a better capacity for global and cognitive functioning of their choreatic group.

So far only a few smaller studies investigated the role of dystonia in HD (Mahant et al., [2003](#brb31704-bib-0010){ref-type="ref"}; Zande et al., [2017](#brb31704-bib-0020){ref-type="ref"}). Zande et al. ([2017](#brb31704-bib-0020){ref-type="ref"}) described a high prevalence of dystonia as being a late symptom correlating with increasing HD stage and disease duration. In addition, a strong relationship with functional status of dystonia and rigidity was described (Carlozzi et al., [2019](#brb31704-bib-0002){ref-type="ref"}). To our knowledge, no study compared three different phenotypes with predominant dystonia, chorea, and hypokinetic‐rigidity which are essential for symptomatic treatments (Saft, von Hein, & Lucke, [2018](#brb31704-bib-0015){ref-type="ref"}; Wojtecki, Groiss, & Ferrea, [2015](#brb31704-bib-0022){ref-type="ref"}; Zittel et al., [2018](#brb31704-bib-0025){ref-type="ref"}). For a better understanding, we investigated whether there are collectives in the European Huntington\'s Disease Network ENROLL‐HD study classified as predominant choreatic, dystonic, and hypokinetic‐rigid in order to compare cognitive, functional, and psychiatric performance data (Landwehrmeyer, Fitzer‐Attas, & Giuliano, [2017](#brb31704-bib-0009){ref-type="ref"}). We hypothesize a better cognitive functioning of a choreatic and dystonic group when compared to a hypokinetic‐rigid group and possibly more depression due to pain in our dystonic subgroup.

2. PATIENTS AND METHODS {#brb31704-sec-0006}
=======================

A total of 7,512 subjects (\>18 years) with manifest HD (diagnostic confidence level: 4; \>36 CAG; total motor score (TMS): \>5) participating in the ENROLL‐HD study were analyzed (Kieburtz et al., [1996](#brb31704-bib-0008){ref-type="ref"}).

Enroll‐HD is a global clinical research platform designed to facilitate clinical research in Huntington\'s disease. Core datasets are collected annually from all research participants as part of this multicentre longitudinal observational study. Data are monitored for quality and accuracy using a risk‐based monitoring approach. All sites are required to obtain and maintain local ethical approval.

For subdividing predominant motor phenotypes, sum scores were calculated according to Hart et al. ([2013](#brb31704-bib-0004){ref-type="ref"}) Scores had to differ by at least one standard deviation compared to the entire cohort. Classification of predominant choreatic (*N* = 606) due to chorea scale and hypokinetic‐rigid (*N* = 369) due to hypokinetic‐rigidity with finger taps, pronate--supinate hands, bradykinesia, and rigidity, phenotypes were identified in UHDRS motor assessment (Hart et al., [2013](#brb31704-bib-0004){ref-type="ref"}). Equally onset and classification of dystonia were evaluated due to items for dystonia in trunk, right, and left upper and lower extremities as part of the UHDRS motor score, and (*N* = 402) subjects were classified as predominant dystonic. Interference with predominant hypokinetic‐rigidity and dystonia (*n* = 661) or smaller deviations were regarded as mixed phenotypes (*n* = 6,135) and excluded.

Differences among group means were assessed using ANOVA with post hoc Tukey\'s HSD tests in IBM SPSS Statistics V.25. Afterward, one‐way ANCOVAs were conducted determining differences between subtypes on functional and cognitive assessments controlling for CAP score (Zhang et al., [2011](#brb31704-bib-0024){ref-type="ref"}), CAG, age, disease duration, and education.

3. RESULTS {#brb31704-sec-0007}
==========

Significant mean differences were detected between choreatic, dystonic, and hypokinetic‐rigid groups regarding all demographic parameters (all *p* \< .001) (Table [1](#brb31704-tbl-0001){ref-type="table"}). Post hoc comparisons indicated CAP score was higher, education level lower, and disease duration longer in hypokinetic compared to dystonic and choreatic group (all *p* \< .001). The CAG mean was lower in the choreatic versus dyston and hypokinetic group (all *p* \< .001). Comparison of age indicated that the dystonic group was younger than choreatic and hypokinetic‐rigid (all *p* \< .001).

###### 

Analysis of demographics, motoric, cognitive, functional, and psychiatric capacities in different motor subtypes

<table><thead><tr class="header"><th></th><th><p>Choreatic (1)</p><p><em>N</em> = 606</p></th><th><p>Dyston (2)</p><p><em>N</em> = 402</p></th><th><p>Hypokinetic‐rigid (3)</p><p><em>N</em> = 369</p></th><th><em>F</em></th><th><em>p</em></th><th>Part. <em>η</em> <sup>2</sup></th><th><em>p</em> (1) versus (2)</th><th><em>p</em> (1) versus (3)</th><th><em>p</em> (2) versus (3)</th></tr></thead><tbody><tr class="odd"><td>Demographic parameters</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr class="even"><td>Age (years); <em>M</em> (<em>SD</em>)</td><td>56.1 (12.0)</td><td>51.2 (13.5)</td><td>55.8 (14.2)</td><td>14.10</td><td>&lt;.001</td><td>0.020</td><td>&lt;.001</td><td>.929</td><td>&lt;.001</td></tr><tr class="odd"><td>CAG high</td><td>43.6 (3.4)</td><td>45.3 (5.3)</td><td>45.4 (5.8)</td><td>23.87</td><td>&lt;.001</td><td>0.034</td><td>&lt;.001</td><td>&lt;.001</td><td>.974</td></tr><tr class="even"><td>Disease duration (years)</td><td>8.6 (5.3)</td><td><p>7.9 (5.5)</p><p><em>n</em> = 400</p></td><td><p>10.3 (5.0)</p><p><em>n</em> = 361</p></td><td>20.96</td><td>&lt;.001</td><td>0.030</td><td>.054</td><td>&lt;.001</td><td>&lt;.001</td></tr><tr class="odd"><td>Education level (ISCED 0–6)</td><td>3.4 (1.2)</td><td><p>3.4 (1.2)</p><p><em>n</em> = 399</p></td><td><p>3.0 (1.3)</p><p><em>n</em> = 366</p></td><td>13.92</td><td>&lt;.001</td><td>0.020</td><td>.874</td><td>&lt;.001</td><td>&lt;.001</td></tr><tr class="even"><td>CAP score</td><td>526.2 (83.2)</td><td>548.1 (92.1)</td><td>589.4 (110.4)</td><td>52.15</td><td>&lt;.001</td><td>0.071</td><td>&lt;.005</td><td>&lt;.001</td><td>&lt;.001</td></tr><tr class="odd"><td>Timed onsets</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr class="even"><td>Age of onset motor symptoms (years)</td><td>47.5 (11.6)</td><td><p>44.0 (13.8)</p><p><em>n</em> = 400</p></td><td><p>45.6 (14.1)</p><p><em>n</em> = 361</p></td><td>8.84</td><td>&lt;.001</td><td>0.013</td><td>&lt;.001</td><td>.072</td><td>.216</td></tr><tr class="odd"><td>Rater's estimate of symptom onset (years)</td><td><p>47.25 (11.9)</p><p><em>n</em> = 572</p></td><td><p>43.2 (13.2)</p><p><em>n</em> = 378</p></td><td><p>44.8 (13.5)</p><p><em>n</em> = 340</p></td><td>12.18</td><td>&lt;.001</td><td>0.019</td><td>&lt;.001</td><td>.013</td><td>.215</td></tr><tr class="even"><td>Date of clinical HD diagnosis (years)</td><td><p>51.2 (12.0)</p><p><em>n</em> = 601</p></td><td><p>46.7 (13.6)</p><p><em>n</em> = 396</p></td><td><p>48.6 (13.9)</p><p><em>n</em> = 362</p></td><td>14.71</td><td>&lt;.001</td><td>0.021</td><td>&lt;.001</td><td>.009</td><td>.102</td></tr><tr class="odd"><td>Symptoms first noticed by participant (years)</td><td><p>48.3 (12.1)</p><p><em>n</em> = 577</p></td><td><p>44.8 (13.4)</p><p><em>n</em> = 374</p></td><td><p>45.8 (13.8)</p><p><em>n</em> = 338</p></td><td>9.09</td><td>&lt;.001</td><td>0.014</td><td>&lt;.001</td><td>.014</td><td>.566</td></tr><tr class="even"><td>Symptoms first noticed by family (years)</td><td><p>47.2 (11.9)</p><p><em>n</em> = 564</p></td><td><p>43.5 (13.5)</p><p><em>n</em> = 375</p></td><td><p>45.2 (13.7)</p><p><em>n</em> = 343</p></td><td>9.41</td><td>&lt;.001</td><td>0.014</td><td>&lt;.001</td><td>.072</td><td>.163</td></tr><tr class="odd"><td>At what age did cognitive impairment first start to have an impact on daily life? (years)</td><td><p>50.1 (12.4)</p><p><em>n</em> = 381</p></td><td><p>46.2 (13.9)</p><p><em>n</em> = 274</p></td><td><p>48.8 (14.5)</p><p><em>n</em> = 302</p></td><td>6.76</td><td>&lt;.005</td><td>0.014</td><td>&lt;.005</td><td>.442</td><td>.050</td></tr><tr class="even"><td>At what age did perseverative obsessive behavior begin? (years)</td><td><p>52.1 (13.5)</p><p><em>n</em> = 333</p></td><td><p>48.1 (14.4)</p><p><em>n</em> = 221</p></td><td><p>49.9 (14.3)</p><p><em>n</em> = 219</p></td><td>5.76</td><td>&lt;.005</td><td>0.015</td><td>&lt;.005</td><td>.167</td><td>.340</td></tr><tr class="odd"><td>At what age did irritability begin? (years)</td><td><p>47.9 (13.3)</p><p><em>n</em> = 413</p></td><td><p>44.2 (14.6)</p><p><em>n</em> = 255</p></td><td><p>47.6 (15.5)</p><p><em>n</em> = 262</p></td><td>5.86</td><td>&lt;.005</td><td>0.012</td><td>&lt;.005</td><td>.951</td><td>.020</td></tr><tr class="even"><td>At what age did depression begin? (years)</td><td><p>47.1 (13.5)</p><p><em>n</em> = 427</p></td><td><p>42.1 (14.4)</p><p><em>n</em> = 298</p></td><td><p>45.5 (14.8)</p><p><em>n</em> = 264</p></td><td>10.95</td><td>&lt;.001</td><td>0.022</td><td>&lt;.001</td><td>.337</td><td>.012</td></tr><tr class="odd"><td>At what age did apathy begin? (years)</td><td><p>51.8 (13.1)</p><p><em>n</em> = 386</p></td><td><p>46.8 (14.2)</p><p><em>n</em> = 251</p></td><td><p>51.1 (14.7)</p><p><em>n</em> = 268</p></td><td>10.92</td><td>&lt;.001</td><td>0.024</td><td>&lt;.001</td><td>.780</td><td>&lt;.005</td></tr><tr class="even"><td>At what age did violent or aggressive behavior begin? (years)</td><td><p>47.7 (14.4)</p><p><em>n</em> = 223</p></td><td><p>44.3 (14.8)</p><p><em>n</em> = 134</p></td><td><p>47.2 (16.1)</p><p><em>n</em> = 189</p></td><td>2.26</td><td>.105</td><td>0.008</td><td>.101</td><td>.939</td><td>.210</td></tr><tr class="odd"><td>At what age did psychosis (hallucinations or delusions) begin? (years)</td><td><p>49.6 (12.7)</p><p><em>n</em> = 61</p></td><td><p>45.9 (15.6)</p><p><em>n</em> = 60</p></td><td><p>49.9 (15.8)</p><p><em>n</em> = 93</p></td><td>1.47</td><td>.231</td><td>0.014</td><td>.359</td><td>.992</td><td>.239</td></tr><tr class="even"><td>Motoric parameter</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr class="odd"><td>TMS (UHDRS)</td><td>50.4 (11.4)</td><td>52.2 (10.3)</td><td>63.5 (10.7)</td><td>180.33</td><td>&lt;.001</td><td>0.208</td><td>.028</td><td>&lt;.001</td><td>&lt;.001</td></tr><tr class="even"><td>Cognitive parameters</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr class="odd"><td>Verbal fluency test (letters): Total correct (in 60 s)</td><td><p>10.7 (4.7)</p><p><em>n</em> = 595</p></td><td><p>9.9 (4.6)</p><p><em>n</em> = 394</p></td><td><p>5.7 (3.8)</p><p><em>n</em> = 319</p></td><td>136.85</td><td>&lt;.001</td><td>0.173</td><td>.021</td><td>&lt;.001</td><td>&lt;.001</td></tr><tr class="even"><td>Verbal fluency test (letters): Total correct (in 180 s)</td><td><p>18.1 (10.5)</p><p><em>n</em> = 472</p></td><td><p>16.1 (9.4)</p><p><em>n</em> = 295</p></td><td><p>8.0 (6.4)</p><p><em>n</em> = 183</p></td><td>75.66</td><td>&lt;.001</td><td>0.138</td><td>&lt;.005</td><td>&lt;.001</td><td>&lt;.001</td></tr><tr class="odd"><td>SDMT: total correct (in 90 s)</td><td><p>19.3 (10.3)</p><p><em>n</em> = 555</p></td><td><p>16.7 (9.0)</p><p><em>n</em> = 377</p></td><td><p>7.0 (7.4)</p><p><em>n</em> = 257</p></td><td>154.71</td><td>&lt;.001</td><td>0.207</td><td>&lt;.001</td><td>&lt;.001</td><td>&lt;.001</td></tr><tr class="even"><td>Stroop color naming test: total correct (in 45 s)</td><td><p>37.3 (14.1)</p><p><em>n</em> = 592</p></td><td><p>35.5 (14.1)</p><p><em>n</em> = 387</p></td><td><p>20.2 (13.7)</p><p><em>n</em> = 311</p></td><td>164.78</td><td>&lt;.001</td><td>0.203</td><td>.113</td><td>&lt;.001</td><td>&lt;.001</td></tr><tr class="odd"><td>Stroop word reading test: total correct (in 45 s)</td><td><p>49.6 (18.6)</p><p><em>n</em> = 581</p></td><td><p>46.3 (18.2)</p><p><em>n</em> = 389</p></td><td><p>25.8 (18.2)</p><p><em>n</em> = 297</p></td><td>173.35</td><td>&lt;.001</td><td>0.215</td><td>.016</td><td>&lt;.001</td><td>&lt;.001</td></tr><tr class="even"><td>Stroop interference test: total correct (in 45 s)</td><td><p>20.3 (9.8)</p><p><em>n</em> = 512</p></td><td><p>18.9 (8.6)</p><p><em>n</em> = 330</p></td><td><p>10.1 (8.2)</p><p><em>n</em> = 198</p></td><td>91.84</td><td>&lt;.001</td><td>0.150</td><td>.076</td><td>&lt;.001</td><td>&lt;.001</td></tr><tr class="odd"><td>Trail making test: Part A time to complete (in seconds)</td><td><p>82.7 (51.0)</p><p><em>n</em> = 437</p></td><td><p>91.9 (54.1)</p><p><em>n</em> = 271</p></td><td><p>151.4 (73.4)</p><p><em>n</em> = 126</p></td><td>75.08</td><td>&lt;.001</td><td>0.153</td><td>.084</td><td>&lt;.001</td><td>&lt;.001</td></tr><tr class="even"><td>Trail making test: Part B time to complete (in seconds)</td><td><p>173.0 (68.1)</p><p><em>n</em> = 415</p></td><td><p>188.9 (63.7)</p><p><em>n</em> = 253</p></td><td><p>223.0 (45.7)</p><p><em>n</em> = 116</p></td><td>28.27</td><td>&lt;.001</td><td>0.068</td><td>.005</td><td>&lt;.001</td><td>&lt;.001</td></tr><tr class="odd"><td>MMSE: total correct</td><td><p>24.5 (4.0)</p><p><em>n</em> = 409</p></td><td><p>23.3 (4.0)</p><p><em>N</em> = 253</p></td><td><p>17.8 (6.1)</p><p><em>n</em> = 156</p></td><td>128.42</td><td>&lt;.001</td><td>0.240</td><td>.005</td><td>&lt;.001</td><td>&lt;.001</td></tr><tr class="even"><td>Functional parameters</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr class="odd"><td>TFC (UHDRS)</td><td>7.3 (2.9)</td><td><p>6.6 (3.1)</p><p><em>n</em> = 401</p></td><td><p>3.2 (2.6)</p><p><em>n</em> = 368</p></td><td>242.07</td><td>&lt;.001</td><td>0.261</td><td>&lt;.005</td><td>&lt;.001</td><td>&lt;.001</td></tr><tr class="even"><td>IS (%)</td><td><p>73.7 (12.8)</p></td><td><p>70.2 (14.2)</p><p><em>n</em> = 400</p></td><td>51.0 (17.5)</td><td>295.26</td><td>&lt;.001</td><td>0.301</td><td>&lt;.005</td><td>&lt;.001</td><td>&lt;.001</td></tr><tr class="odd"><td>Psychiatric parameters</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr class="even"><td>PBA‐s: sum score apathy</td><td><p>3.6 (4.3)</p><p><em>n</em> = 604</p></td><td><p>3.9 (4.5)</p><p><em>n</em> = 400</p></td><td><p>6.6 (5.8)</p><p><em>n</em> = 358</p></td><td>49.71</td><td>&lt;.001</td><td>0.068</td><td>.604</td><td>&lt;.001</td><td>&lt;.001</td></tr><tr class="odd"><td>PBA‐s: sum score executive function</td><td><p>3.8 (5.8)</p><p><em>n</em> = 599</p></td><td><p>4.3 (6.1)</p><p><em>n</em> = 399</p></td><td><p>5.7 (7.1)</p><p><em>n</em> = 348</p></td><td>9.93</td><td>&lt;.001</td><td>0.015</td><td>.463</td><td>&lt;.001</td><td>.007</td></tr><tr class="even"><td>PBA‐s: sum score depression</td><td><p>4.9 (6.5)</p><p><em>n</em> = 603</p></td><td><p>5.0 (6.0)</p><p><em>n</em> = 401</p></td><td><p>4.8 (6.2)</p><p><em>n</em> = 356</p></td><td>0.093</td><td>.911</td><td>0.000</td><td>.981</td><td>.956</td><td>.903</td></tr><tr class="odd"><td>PBA‐s: sum score irritability, aggression</td><td><p>3.5 (5.1)</p><p><em>n</em> = 604</p></td><td><p>2.9 (4.7)</p><p><em>n</em> = 401</p></td><td><p>4.1 (6.2)</p><p><em>n</em> = 368</p></td><td>4.90</td><td>.008</td><td>0.007</td><td>.199</td><td>.190</td><td>.05</td></tr><tr class="even"><td>PBA‐s: sum score psychosis</td><td><p>0.4 (2.2)</p><p><em>n</em> = 603</p></td><td><p>0.4 (1.9)</p><p><em>n</em> = 398</p></td><td><p>0.5 (2.4)</p><p><em>n</em> = 355</p></td><td>0.516</td><td>.597</td><td>0.001</td><td>.984</td><td>.665</td><td>.617</td></tr><tr class="odd"><td>HADS‐SIS: depression subscore</td><td><p>6.2 (3.9)</p><p><em>n</em> = 386</p></td><td><p>6.6 (4.4)</p><p><em>n</em> = 200</p></td><td><p>7.4 (4.6)</p><p><em>n</em> = 135</p></td><td>3.96</td><td>.019</td><td>0.011</td><td>.511</td><td>.014</td><td>.226</td></tr><tr class="even"><td>HADS‐SIS: irritability subscore</td><td><p>6.0 (4.5)</p><p><em>n</em> = 385</p></td><td><p>5.7 (5.0)</p><p><em>n</em> = 200</p></td><td><p>5.0 (4.1)</p><p><em>n</em> = 134</p></td><td>2.42</td><td>.090</td><td>0.007</td><td>.716</td><td>.073</td><td>.360</td></tr><tr class="odd"><td>HADS‐SIS: outward irritability subscore</td><td><p>3.6 (2.7)</p><p><em>n</em> = 387</p></td><td><p>3.3 (2.8)</p><p><em>n</em> = 201</p></td><td><p>3.3 (2.8)</p><p><em>n</em> = 135</p></td><td>0.776</td><td>.461</td><td>0.002</td><td>.553</td><td>.599</td><td>.998</td></tr><tr class="even"><td>HADS‐SIS: inward irritability subscore</td><td><p>2.4 (2.4)</p><p><em>n</em> = 387</p></td><td><p>2.4 (2.9)</p><p><em>n</em> = 201</p></td><td><p>1.7 (2.1)</p><p><em>n</em> = 135</p></td><td>4.36</td><td>.013</td><td>0.012</td><td>.974</td><td>.011</td><td>.042</td></tr><tr class="odd"><td>HADS‐SIS: anxiety subscore</td><td><p>6.0 (4.2)</p><p><em>n</em> = 387</p></td><td><p>6.0 (4.7)</p><p><em>n</em> = 200</p></td><td><p>5.2 (3.8)</p><p><em>n</em> = 132</p></td><td>1.94</td><td>.144</td><td>0.005</td><td>.989</td><td>.133</td><td>.239</td></tr></tbody></table>

Statistical data given as a comparison of mean values (standard deviation) between choreatic, dystonic, and hypokinetic‐rigid groups using ANOVA and post hoc tests (Tukey\'s HSD).

Abbreviations: *F*, *F* value; HADS‐SIS, Hospital Anxiety and Depression Scale; IS, Independence Scale; M, mean; MMSE, Mini‐Mental State Examination; *p*, *p* value; Part *η* ^2^, effect size; PBA‐s, problem behaviors assessment; *SD*, standard deviation; SDMT, symbol digit modality test; TFC, total functional score; TMS, total motor score.

John Wiley & Sons, Ltd

Analysis of motoric manifestation verified a higher UHDRS‐TMS for hypokinetic subjects when compared to other groups (all *p* \< .001). The dystonic group had earlier motoric onset when compared to choreatic (*p* \< .001) but not to hypokinetic‐rigid subjects (*p* = .216). Comparisons of choreatic versus hypokinetic did not differ in means (*p* = .072). Timed onsets for the rater\'s estimation date of HD diagnosis and symptoms noticed by participant and family differed in same manner as described for motoric manifestation.

Differences regarding cognitive capacity revealed lower performance of hypokinetic if compared to choreatic or dystonic participants (all *p* \< .001). Differences of the choreatic versus dystonic group were not significant except for better performance in SDMT (*p* \< .001) and verbal fluency (180 s; *p* \< .005).

Functional capacities differed for the UHDRS‐total functional capacity (TFC) score and Independence Scale (IS) (all *p* \< .001) detecting choreatic with better capacities compared to dystonic (all *p* \< .005) and hypokinetic (all *p* \< .001). Post hoc tests indicated better functionality for the dystonic versus the hypokinetic group (all *p* \< .001).

Beside higher apathy scores for hypokinetic versus. dystonic and choreatic (all *p* \< .001) and executive function (choreatic vs. hypokinetic; *p* \< .001), the psychiatric scores revealed no group differences.

One‐way ANCOVAs determined effects in cognitive and functional scores remained significant (all *p* \< .001) after controlling for covariates (Table [2](#brb31704-tbl-0002){ref-type="table"}). Controlling for the covariate CAP score indicated highest effect‐ changes (in partial *η* ^2^) compared to other covariates.

###### 

Analysis of cognitive and functional capacities in choreatic, dystonic, and hypokinetic‐rigid motor subtypes controlling for covariates

  ANCOVA                     Mot. Phenotype (choreatic, dystonic, hypokinetic)   With covariate CAP score   With covariate CAG high   With covariate age   With covariate disease duration   With covariate education                                                                                                   
  -------------------------- --------------------------------------------------- -------------------------- ------------------------- -------------------- --------------------------------- -------------------------- -------- -------- ------- -------- -------- ------- -------- -------- ------- -------- -------- -------
  SDMT                       154.71                                              \<.001                     0.207                     128.26               \<.001                            0.178                      156.44   \<.001   0.209   156.73   \<.001   0.209   142.24   \<.001   0.195   141.51   \<.001   0.193
  Verbal fluency (letters)   136.85                                              \<.001                     0.173                     111.95               \<.001                            0.147                      136.60   \<.001   0.173   137.38   \<.001   0.174   124.81   \<.001   0.162   124.64   \<.001   0.161
  Stroop color naming        164.28                                              \<.001                     0.203                     141.91               \<.001                            0.181                      172.56   \<.001   0.212   166.38   \<.001   0.206   150.18   \<.001   0.190   150.43   \<.001   0.190
  Stroop word reading        173.35                                              \<.001                     0.215                     145.63               \<.001                            0.187                      176.54   \<.001   0.218   175.23   \<.001   0.217   157.69   \<.001   0.201   158.29   \<.001   0.201
  Stroop interference        91.84                                               \<.001                     0.150                     82.05                \<.001                            0.137                      104.12   \<.001   0.167   98.47    \<.001   0.160   83.24    \<.001   0.139   82.04    \<.001   0.137
  TFC                        242.08                                              \<.001                     0.261                     202.88               \<.001                            0.228                      240.65   \<.001   0.260   242.69   \<.001   0.261   215.31   \<.001   0.240   225.16   \<.001   0.249
  IS                         295.27                                              \<.001                     0.301                     248.82               \<.001                            0.266                      294.40   \<.001   0.300   296.50   \<.001   0.302   266.36   \<.001   0.281   278.75   \<.001   0.290

Comparison of mean values.

Abbreviations: *F*, *F* value; IS, Independence Scale; *p*, *p* value; Part *η* ^2^, effect size; SDMT, symbol digit modality test; TFC, total functional score.

John Wiley & Sons, Ltd

4. DISCUSSION {#brb31704-sec-0008}
=============

To our knowledge, this is the first study comprising data coming from a large cohort of manifest HD patients analyzing subjects with motor symptoms in terms of predominantly dystonia compared to choreatic and hypokinetic‐rigid regarding their cognitive, functional, and psychiatric performance.

If compared to hypokinetic‐rigids, no differences regarding onsets were observed in the dystonic group except for earlier apathy. Contrary dystonic participants showed earlier onsets compared to choreatic. In contrast to earlier publication, no difference was observed for the choreatic compared to the hypokinetic‐rigid group even if CAG repeats and the CAP score were significantly lower in the choreatic group (Hart et al., [2013](#brb31704-bib-0004){ref-type="ref"}). It is reasonably possible that in previous research, dystonic patients were implemented partly within a hypokinetic‐rigid cohort. As mentioned, we identified a large cohort (*n* = 661) of patients with interfering dystonic and hypokinetic‐rigid motor subtypes which were excluded from our analysis. Former research might have implemented these patients in their analysis which might explain the different effects regarding onsets.

Former research described dystonia as a symptom which is related to increased HD stages with longer motor disease duration (Zande et al., [2017](#brb31704-bib-0020){ref-type="ref"}). In our large cohort, dystonic patients were younger than predominant choreatic and hypokinetic‐rigid patients (all *p* \< .001). Additionally, if compared to choreatic subjects (*p* = .054), the disease duration of dystonic participants did not differ. Hence, we assumed that dystonia may occur early and is not solely accompanied with longer disease durations, which is unexpected and partly in opposite to earlier findings.

Moreover dystonia seems to have an early impact since patients and families notice symptoms earlier than in the choreatic group (all *p* \< .001). These results go along with dystonia research data additionally describing patients suffering from pain and emotional harm caused by dystonia with a high impact on the quality of life (Bernstein et al., [2016](#brb31704-bib-0001){ref-type="ref"}; Torres & Rosales, [2017](#brb31704-bib-0019){ref-type="ref"}).

Regarding most tasks for cognition and TMS, there was no difference between the dystonic and the choreatic group, except for SDMT which might be due to a motor impairment and verbal fluency (180 s) for letters. Dystonic patients showed better cognitive performance in all categories when compared to hypokinetic‐rigid patients (all *p* \< .001).

Comparison of TFC was different in all groups, whereas dystonic patients ranged in‐between choreatic with higher and hypokinetic‐rigid with lower capacities. Thus, recent research describing greater impact of dystonia and rigidity compared to chorea on functionality can be confirmed in a large cohort (Carlozzi et al., [2019](#brb31704-bib-0002){ref-type="ref"}).

Group differences were found for CAG repeats, disease duration, education, TMS, and CAP score, with lower CAG repeats in the choreatic group versus the hypokinetic‐rigid (*p* \< .001) but also for the choreatic versus the dystonic group (*p* \< .001). Since differences might have an impact, we focused on controlling these which resulted in no change in findings for cognitive and functional capacities. Thus, group differences are not because of underlying effects from varying covariates.

Apart from an increased apathy sum score in the hypokinetic‐rigid group versus the dystonic and choreatic group, we did not observe any differences in the severity of psychiatric symptoms between groups. Besides, less executive function was observed in the hypokinetic versus the choreatic group (PBA score). This is remarkable because patients with focal dystonia complained about increased psychiatric symptoms with depression, anxiety, and obsessive‐compulsive disorders (Jahanshahi, [2017](#brb31704-bib-0007){ref-type="ref"}). We therefore initially hypothesize that dystonia may lead to more depression in HD which is however not supported by our data. Hereby, unawareness in HD patients might be a possible explanation (Hergert, Haaland, & Cimino, [2019](#brb31704-bib-0005){ref-type="ref"}; Hergert, Sanchez‐Ramos, & Cimino, [2019](#brb31704-bib-0006){ref-type="ref"}; McCusker & Loy, [2014](#brb31704-bib-0011){ref-type="ref"}; Sitek, Thompson, Craufurd, & Snowden, [2014](#brb31704-bib-0017){ref-type="ref"}). According to our data, functional status and cognition seem not primary influenced by psychiatric status.

5. CONCLUSION {#brb31704-sec-0009}
=============

In summary, we were able to confirm better cognitive capacity of choreatic versus hypokinetic‐rigid patients and extend this knowledge to dystonic patients showing a cognitive capacity similar to choreatic. In this study, we identified and characterized a large cohort of dystonic HD patients for the first time. Motoric phenotypes are relevant for functional and cognitive capacities independent from described co‐variates. On the one hand, dystonic patients seem to have a similar onset to hypokinetic‐rigid patients, but on the other hand, a cognitive performance is similar to choreatic patients, which is not explained by higher CAG repeats, CAP scores, age, disease duration, or education.
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